ACP
AVDL

Acuta Capital Partners’s Avadel Pharmaceuticals AVDL Stock Holding History

Acuta Capital Partners’s Portfolio AVDL Stock Details AVDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-250,000
Closed -$2.45M – 39
2021
Q3 		$2.45M Buy
+250,000
New +$1.97M 0.86% 32

Other funds holding AVDL

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GJL
Gendell Jeffrey L $7.34B AUM 183.72% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
BIP
Brandes Investment Partners La Jolla, California $14.1B AUM 25.52% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
WE
Wealth Effects Boston, Massachusetts $370M AUM 97.79% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acuta Capital Partners's AVDL Position: Q2 2022 in Review

Acuta Capital Partners sold out of Avadel Pharmaceuticals (AVDL) in Q2 2022, closing a stake of 580,000 shares — an estimated $3.96M sold.

Acuta Capital Partners first reported a position in AVDL in Q4 2019 and held it in 8 quarters. The position peaked at $20.9M in Q1 2020. 82 funds tracked by Wall St. Rank hold AVDL as of Q2 2022.

  • Acuta Capital Partners reported no remaining Avadel Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Acuta Capital Partners sold 580,000 Avadel Pharmaceuticals shares in Q2 2022, an estimated $3.96M.
  • Acuta Capital Partners first reported a position in Avadel Pharmaceuticals in Q4 2019 and held it in 8 quarters.
  • Acuta Capital Partners's Avadel Pharmaceuticals position peaked at $20.9M in Q1 2020.
  • 82 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q2 2022.

Based on Acuta Capital Partners's 13F filing for Q2 2022, filed 15 Aug 2022.